BioSpace News Archive

DexCom, Inc. announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023.

Today, the U.S. Food and Drug Administration announced a proposed rule regarding laboratory developed tests, or LDTs, which play an important role in healthcare.

Sharps Technology, Inc. announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data showing that disrupting the recommended TEPEZZA treatment regimen by lengthening the amount of time between infusions can increase the need for a second course of treatment.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases today announced financial results and highlights for the first half of 2023, ended June 30th.

Promontory Therapeutics Inc., a clinical stage biotechnology company advancing immunogenic small molecule approaches in oncology, has become the first international company to gain membership in the Paris-Saclay Cancer Center, an emerging European hub for cancer research and innovation.

Portage Biotech Inc. announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock, at a purchase price of $1.90 per share.

On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso’s globally first PD-1/CTLA-4 bispecific antibody, cadonilimab (trade name: 开坦尼®), and RemeGen’s first domestically developed antibody-drug conjugate (ADC) injection,

Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.

RaySearch Laboratories AB is pleased to announce that the longterm collaboration/partnership with the innovative center EBG MedAustron GmbH in Wiener Neustadt in Austria will be further expanded through a new research agreement.